Artiva Biotherapeutics (ARTV) Share-based Compensation (2023 - 2026)

Artiva Biotherapeutics (ARTV) has 4 years of Share-based Compensation data on file, last reported at $1.6 million in Q1 2026.

• Share-based Compensation for Q1 2026 came in at $1.6 million, down 22.37% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.4 million (down 16.57% YoY), and the FY2025 annual result was $6.8 million, down 2.28% from the prior year.
• Share-based Compensation was little changed at $1.6 million in Q1 2026 per ARTV's latest filing, from $1.6 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $2.2 million in Q4 2024 and troughed at $1.4 million in Q3 2023.
• A 4-year average of $1.7 million and a median of $1.6 million in 2025 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2024 and 2025: Share-based Compensation jumped 56.9% in 2024, then dropped 27.24% in 2025.
• A 4-year view of Share-based Compensation shows it stood at $1.4 million in 2023, then surged by 56.9% to $2.2 million in 2024, then fell by 27.24% to $1.6 million in 2025, then increased by 0.25% to $1.6 million in 2026.
• Business Quant data shows ARTV's Share-based Compensation at $1.6 million in Q1 2026, $1.6 million in Q4 2025, and $1.6 million in Q3 2025.